Does Biosilicon deliver? Uni of Pittsburgh to investigate
Friday, 21 May, 2004
Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
The company will work with the laboratory of Prof Ted Ross, which has experience in developing DNA vaccines for viral diseases to build on prior work performed by pSiMedica on the loading into and release of DNA from BioSilicon matrices to effectively produce the immunogen carried by the DNA sequence.
pSivida managing director Gavin Rezos said the agreement demonstrated the increasing profile of pSivida and pSiMedica in the US.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
